Brick & Kyle Associates’s Myriad Genetics MYGN Stock Holding History

Brick & Kyle Associates’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,849	Closed	-$74K	–	257
2017 Q1	$74K	Hold	3,849	–	–	0.06%	141
2016 Q4	$64K	Hold	3,849	–	–	0.05%	155
2016 Q3	$79K	Hold	3,849	–	–	0.06%	140
2016 Q2	$118K	Sell	3,849 -300	-7%	-$10.4K	0.1%	113
2016 Q1	$155K	Hold	4,149	–	–	0.13%	96
2015 Q4	$179K	Sell	4,149 -300	-7%	-$12.7K	0.16%	89
2015 Q3	$167K	Hold	4,449	–	–	0.16%	96
2015 Q2	$151K	Hold	4,449	–	–	0.13%	107
2015 Q1	$157K	Sell	4,449 -500	-10%	-$17.9K	0.13%	106
2014 Q4	$169K	Buy	+4,949	New	+$176K	0.15%	102

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Brick & Kyle Associates's MYGN Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 3,849 shares — an estimated $74K sold.

Brick & Kyle Associates first reported a position in MYGN in Q4 2014 and held it in 10 quarters. The position peaked at $179K in Q4 2015. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

Brick & Kyle Associates reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 3,849 Myriad Genetics shares in Q2 2017, an estimated $74K.
Brick & Kyle Associates first reported a position in Myriad Genetics in Q4 2014 and held it in 10 quarters.
Brick & Kyle Associates's Myriad Genetics position peaked at $179K in Q4 2015.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.